Optimising Lung Surfactant Protein Production In The IUGR Fetus At Risk Of Preterm Delivery
Funder
National Health and Medical Research Council
Funding Amount
$463,853.00
Summary
Pregnant women at risk of preterm labour after 24 weeks gestation are increasingly administered glucocorticoids in Australian hospitals in order to promote fetal lung maturation and a successful transition to extrauterine life. Antenatal glucocorticoid treatment reduces overall neonatal mortality, the risk of respiratory distress syndrome and the need for respiratory support. Babies that are born small may not benefit from this treatment in the same way that average size babies benefit.
G-CSF: A Pathogenic Effector In Chronic Obstructive Pulmonary Disease And Its Comorbidities
Funder
National Health and Medical Research Council
Funding Amount
$1,241,551.00
Summary
Chronic Obstructive Pulmonary Disease (COPD) is an incurable lung disease that is a huge global health burden, and new therapies are urgently needed. We have recently discovered a possible cause of COPD. This single factor also appears to drive other associated medical problems that are the biggest contributors to patient deterioration. Using advanced genetics, biochemistry and molecular methods we are searching for ways to turn our discovery into effective treatments for this fatal disease.
A Novel Approach To Restoration Of Tumour Suppression In Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$598,604.00
Summary
Loss of a tumour suppressor is a key event in every cancer, including lung cancer. Therefore restoration of the expression and/or activity of the tumour suppressor is an attractive approach to anti-cancer treatment. In order to restore tumour suppression, a detailed understanding of the mechanism by which a given tumour suppressor is regulated is required. This application focuses on our discovery of a novel mechanism by which a key tumour suppressor of lung cancer is regulated.
Circulatory Biomarkers For Idiopathic Pulmonary Fibrosis: Improving Patient Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$841,625.00
Summary
We are going to find molecules in the blood that would improve the diagnosis and treatment of a lung condition called Idiopathic Pulmonary Fibrosis (IPF). The project brings together well characterized patients from the Australian IPF registry, blood samples we have collected from them and cutting edge technologies to complete this project.
The Link Between Vitamin D Deficiency And Chronic Lung Disease Is Due To Increased Airway Smooth Muscle
Funder
National Health and Medical Research Council
Funding Amount
$644,067.00
Summary
Vitamin D deficiency is a global public health problem. It is becoming increasingly evident that vitamin D deficiency increases the severity of chronic lung disease. In this study we propose to examine a mechanism that we think clearly explains this association. These studies are critical to understanding how deficiencies in key nutrients can impact on chronic lung disease and will provide the data necessary to guide public health policy to reduce the burden of disease in the community.
Role Of Viruses In The Development Of Lung Disease In Cystic Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$1,223,186.00
Summary
This study will investigate how lung disease starts in babies with cystic fibrosis and the role of viral infections in this process. The new knowledge gained will help us move towards treatments that prevent or delay the start of lung disease, something not currently possible. We believe this new treatment paradigm will lead to improved quality and extent of life of those with cystic fibrosis.
Molecular Dissection Of Aberrant IL6/gp130 And TGF? Signaling In The Pathogenesis Of Interstitial Pneumonitis
Funder
National Health and Medical Research Council
Funding Amount
$590,009.00
Summary
Interstitial pneumonia (IP) is frequently observed in the group of lung diseases which affect the transfer of oxygen from inhaled air into the bloodstream. Current treatments for these diseases only effectively manage patient’s symptoms but don’t cure patients of IP. We have developed a strategy to identify the exact cell type responsible for an acute IP and the molecular intermediates that may offer novel treatments and pave the way for a possible cure for this disease.
The Predictors Of Asthma And Lung Function Deficits In The Third Decade: Longitudinal Study Of MACS Sibships
Funder
National Health and Medical Research Council
Funding Amount
$1,176,908.00
Summary
This will be the world’s first birth cohort study to use substantial prospective data to investigate how biological, psychosocial, and environmental markers from birth will predict asthma and lung function in the third decade of life. Our findings will be crucial to the development of new policy and practice for the prevention and management of these conditions and uncover crucial risk factors for young adult asthma.
Role Of The LIM-only Protein LMO4 In Lung Development And Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$490,395.00
Summary
Lung cancer is the leading cause of death in cancer patients in Australia. Although treatments have improved in the past 10 years, new therapeutic strategies are eagerly awaited. Deregulation of molecules driving development of normal tissue is often observed in cancer. Our aim is to identify key regulators of lung development and lung repair after injury. We aim to evaluate the role of these molecules in the initiation and progression of lung cancer to identify new targets for therapies.
A POPULATION-BASED COHORT INVESTIGATION OF LUNG FUNCTION IN RELATION TO EARLY LIFE LOWER RESPIRATORY TRACT ILLNESS AND AEROALLERGN SENSITISATION
Funder
National Health and Medical Research Council
Funding Amount
$456,013.00
Summary
Infancy appears to be the critical developmental window during which important alterations in lung structure and function develop. In this study we will assess how early lung function evolves in relation to potential insults such as lower respiratory tract infections and allergic inflammation. These are the mechanisms by which asthma is thought to develop. We will use exciting new lung function tests to evaluate lung function abnormalities associated with peripheral dysfunction characteristic of ....Infancy appears to be the critical developmental window during which important alterations in lung structure and function develop. In this study we will assess how early lung function evolves in relation to potential insults such as lower respiratory tract infections and allergic inflammation. These are the mechanisms by which asthma is thought to develop. We will use exciting new lung function tests to evaluate lung function abnormalities associated with peripheral dysfunction characteristic of chronic airway disease such as asthma.Read moreRead less